1
|
Marani A, Bianchelli T, Gesuita R, Faragalli A, Foti C, Malara G, Micali G, Amerio P, Rongioletti F, Corazza M, Patrizi A, Peris K, Pimpinelli N, Parodi A, Fargnoli MC, Cannavo SP, Pigatto P, Pellacani G, Ferrucci SM, Argenziano G, Cusano F, Stingeni L, Potenza MC, Romanelli M, Bianchi L, Offidani A, Campanati A. Gender differences in adult atopic dermatitis and clinical implication: Results from a nationwide multicentre study. J Eur Acad Dermatol Venereol 2024; 38:375-383. [PMID: 37857489 DOI: 10.1111/jdv.19580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Accepted: 10/06/2023] [Indexed: 10/21/2023]
Abstract
BACKGROUND Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults. However, limited research has been conducted on gender differences in AD. OBJECTIVES This study aimed to assess gender differences in adult AD patients, focusing on demographic and clinical features, comorbidities and treatment approaches. METHODS In this multicentre, observational, cross-sectional study, we enrolled 686 adult patients with AD (357 males and 329 females). For each patient, we collected demographic data (age and sex), anthropometric measurements (weight, height, hip circumference, waist circumference and waist-to-hip ratio), clinical information (onset age, disease duration, severity, itching intensity, impact on quality of life) and noted comorbidities (metabolic, atopic and other). We recorded past and current topical and systemic treatments. We analysed all collected data using statistical techniques appropriate for both quantitative and qualitative variables. Multiple correspondence analysis (MCA) was employed to evaluate the relationships among all clinical characteristics of the patients. RESULTS We found no differences in age at onset, disease duration, severity and quality of life impact between males and females. Males exhibited higher rates of hypertriglyceridaemia and hypertension. No significant gender differences were observed in atopic or other comorbidities. Treatment approaches were overlapping, except for greater methotrexate use in males. MCA revealed distinct patterns based on gender, disease severity, age of onset, treatment and quality of life. Adult males with AD had severe disease, extensive treatments and poorer quality of life, while adult females had milder disease, fewer treatments and moderate quality of life impact. CONCLUSIONS Our study reveals that gender differences in adult AD patients are largely due to inherent population variations rather than disease-related disparities. However, it highlights potential undertreatment of females with moderate AD and quality of life impact, emphasizing the need for equitable AD treatment. JAK inhibitors may offer a solution for gender-based therapeutic parity.
Collapse
Affiliation(s)
- A Marani
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - T Bianchelli
- Dermatology Unit, Istituto Nazionale, INRCA-IRCCS Hospital, Ancona, Italy
| | - R Gesuita
- Centre of Epidemiology and Biostatistics, Polytechnic Marche University, Ancona, Italy
| | - A Faragalli
- Centre of Epidemiology and Biostatistics, Polytechnic Marche University, Ancona, Italy
| | - C Foti
- Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, Bari, Italy
| | - G Malara
- Department of Dermatology Grande, Ospedale Metropolitano "Bianchi Melacrino Morelli", Reggio Calabria, Italy
| | - G Micali
- Dermatology Clinic, University of Catania, PO G. Rodolico, AOU Policlinico-Vittorio Emanuele, Catania, Italy
| | - P Amerio
- Dermatology Unit, Department of Medicine and Aging Science, University G.D'Annunzio Chieti, Chieti, Italy
| | - F Rongioletti
- Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - M Corazza
- Dermatology Unit, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| | - A Patrizi
- Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - K Peris
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Dermatologia, Rome, Italy
- Sezione di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy
- Oncologia Medica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - N Pimpinelli
- Department Health Science Section of Dermatology, University of Florence, Florence, Italy
| | - A Parodi
- Dermatology Clinic, Ospedale Policlinico San Martino, Genoa, Italy
| | - M C Fargnoli
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - S P Cannavo
- Dermatology Unit, University Hospital Policlinico "G. Martino", Messina, Italy
| | - P Pigatto
- Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
| | - G Pellacani
- Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
| | - S M Ferrucci
- Department of Physiopathology and Transplantation, Università Degli Studi Di Milano, Milan, Italy
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - G Argenziano
- Dermatology Unit, University of Campania, Naples, Italy
| | - F Cusano
- Unit of Dermatology, G. Rummo Hospital, Benevento, Italy
| | - L Stingeni
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | - M C Potenza
- Dermatology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome - Polo Pontino, Rome, Italy
| | - M Romanelli
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - L Bianchi
- Dermatology Unit, Policlinico Tor Vergata Rome, University of Rome Tor Vergata, Rome, Italy
| | - A Offidani
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - A Campanati
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| |
Collapse
|
2
|
Stingeni L, Bianchi L, Antonelli E, Caroppo ES, Ferrucci SM, Ortoncelli M, Fabbrocini G, Nettis E, Schena D, Napolitano M, Gola M, Bonzano L, Rossi M, Belloni Fortina A, Balato A, Peris K, Foti C, Guarneri F, Romanelli M, Patruno C, Savoia P, Fargnoli MC, Russo F, Errichetti E, Bianchelli T, Bianchi L, Pellacani G, Feliciani C, Offidani A, Corazza M, Micali G, Milanesi N, Malara G, Chiricozzi A, Tramontana M, Hansel K, Bini V, Buligan C, Caroppo F, Bello GD, Dastoli S, De Brizi EV, Del Giudice MBDF, Diluvio L, Esposito M, Gelmetti A, Giacchetti A, Grieco T, Iannone M, Macchia L, Marietti R, Musumeci ML, Peccerillo F, Pluchino F, Radi G, Ribero S, Romita P, Tavecchio S, Tronconi G, Veronese F. Moderate to severe atopic dermatitis in adolescents treated with dupilumab: a multicenter Italian real-world experience. J Eur Acad Dermatol Venereol 2022; 36:1292-1299. [PMID: 35412683 PMCID: PMC9542087 DOI: 10.1111/jdv.18141] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2021] [Revised: 02/12/2022] [Accepted: 03/23/2022] [Indexed: 11/26/2022]
Abstract
Background Moderate‐to‐severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side‐effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real‐world study on the effectiveness and safety of dupilumab in adolescents (aged from ≥12 to <18 years) with moderate‐to‐severe AD was conducted. The main AD clinical phenotypes were also examined. Methods Data of adolescents with moderate‐to‐severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. Results One hundred and thirty‐nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait‐like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS‐CoV‐2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty‐eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. Conclusions Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID‐19 pandemic era.
Collapse
Affiliation(s)
- L Stingeni
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | - L Bianchi
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | - E Antonelli
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | - E S Caroppo
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | - S M Ferrucci
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - M Ortoncelli
- Division of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - G Fabbrocini
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - E Nettis
- Department of Emergency and Organ Transplantation, Allergology and Clinical Immunology, University of Bari, Bari, Italy
| | - D Schena
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - M Napolitano
- Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
| | - M Gola
- Unit of Allergological and Pediatric Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| | - L Bonzano
- Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - M Rossi
- Department of Dermatology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - A Belloni Fortina
- Unit of Dermatology, Department of Medicine DIMED, University of Padua, Padua, Italy
| | - A Balato
- Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy
| | - K Peris
- Institute of Dermatology, Catholic University, Rome, Italy
| | - C Foti
- Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy
| | - F Guarneri
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - M Romanelli
- Dermatology Unit, University of Pisa, Pisa, Italy
| | - C Patruno
- Section of Dermatology, Health Sciences Department, Magna Graecia University, Catanzaro, Italy
| | - P Savoia
- Dermatology Clinic, Department of Health Science, University of Eastern Piedmont, Novara, Italy
| | - M C Fargnoli
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - F Russo
- Section of Dermatology, Department of Clinical, Surgical Medicine and Neuroscience, University of Siena, Siena, Italy
| | - E Errichetti
- Institute of Dermatology, Department of Medicine (DAME), University of Udine, Udine, Italy
| | - T Bianchelli
- Dermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, INRCA-IRCCS Hospital, Ancona, Italy
| | - L Bianchi
- Dermatology Unit, System Medicine Department, University of Tor Vergata, Rome, Italy
| | - G Pellacani
- Department of Dermatology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
| | - C Feliciani
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | - A Offidani
- Dermatology Clinic, Clinical and Molecular Science Department, Polytechnic Marche University, Ancona, Italy
| | - M Corazza
- Section of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| | - G Micali
- Dermatology Clinic, University of Catania, Catania, Italy
| | - N Milanesi
- Allergological and Occupational Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
| | - G Malara
- Dermatology Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy
| | - A Chiricozzi
- Institute of Dermatology, Catholic University, Rome, Italy
| | - M Tramontana
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | - K Hansel
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Campanati A, Bianchelli T, Gesuita R, Foti C, Malara G, Micali G, Amerio P, Rongioletti F, Corazza M, Patrizi A, Peris K, Pimpinelli N, Parodi A, Fargnoli MC, Cannavo SP, Pigatto P, Pellacani G, Ferrucci SM, Argenziano G, Cusano F, Fabbrocini G, Stingeni L, Potenza MC, Romanelli M, Bianchi L, Offidani A. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study. Arch Dermatol Res 2021; 314:605-607. [PMID: 34235586 DOI: 10.1007/s00403-021-02266-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- A Campanati
- Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche University, Ancona, Italy
| | - T Bianchelli
- Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche University, Ancona, Italy
| | - R Gesuita
- Centre of Epidemiology and Biostatistics, Polytechnic Marche University, Ancona, Italy
| | - C Foti
- Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, Bari, Italy
| | - G Malara
- Department of Dermatology Grande, Ospedale Metropolitano "Bianchi Melacrino Morelli", Reggio Calabria, Italy
| | - G Micali
- Dermatology Clinic, University of Catania, PO G. Rodolico, AOU Policlinico-Vittorio Emanuele, Catania, Italy
| | - P Amerio
- Department of Medicine and Aging Science, Dermatology Unit, University G.D'Annunzio Chieti, Chieti, Italy
| | | | - M Corazza
- Department of Medical Sciences, Dermatology Unit, University of Ferrara, Ferrara, Italy
| | - A Patrizi
- Department of Experimental, Diagnostic and Specialty Medicine, Division of Dermatology, University of Bologna, Bologna, Italy.
| | - K Peris
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Dermatologia, Rome, Italy.,Sezione di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy.,Oncologia Medica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - N Pimpinelli
- Department Health Science Section of Dermatology, University of Florence, Florence, Italy
| | - A Parodi
- Dermatology Clinic, Ospedale Policlinico San Martino, Largo R. Benzi, 10, 16132, Genoa, Italy
| | - M C Fargnoli
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - S P Cannavo
- Dermatology Unit, University Hospital Policlinico "G. Martino", Messina, Italy
| | - P Pigatto
- Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
| | - G Pellacani
- Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Science With Interest Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - S M Ferrucci
- Department of Physiopathology and Transplantation, Università Degli Studi Di Milano, Milan, Italy.,Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Pace, 9, 20122, Milan, Italy
| | - G Argenziano
- Dermatology Unit, University of Campania, Naples, Italy
| | - F Cusano
- Unit of Dermatology, G. Rummo Hospital, Benevento, Italy
| | - G Fabbrocini
- Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Naples, Italy
| | - L Stingeni
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | - M C Potenza
- Dermatology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome - Polo Pontino, Rome, Italy
| | - M Romanelli
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - L Bianchi
- Dermatology Unit, Policlinico Tor Vergata Rome, University of Rome Tor Vergata, Rome, Italy
| | - A Offidani
- Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche University, Ancona, Italy
| | | |
Collapse
|
4
|
Malara G, Trifirò C, Bartolotta A, Giofré C, D'Arrigo G, Testa A, De Lorenzo A, Tripepi G. Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. Eur Rev Med Pharmacol Sci 2021; 25:406-412. [PMID: 33506930 DOI: 10.26355/eurrev_202101_24408] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Guselkumab is a fully human monoclonal IgG1 antibody which, by selectively binding to the p19 subunit of IL-23, prevents it from binding to the IL-23 receptor on the cell surfaces. To date, no prospective data are available on the efficacy and safety of this drug in everyday clinical practice in patients with psoriasis (PSO). MATERIALS AND METHODS This is a longitudinal, single arm, real-world, prospective study to investigate the effect of Guselkumab on PSO and quality of life (DLQI) in 44 PSO patients. Outcomes were PASI, BSA, DLQI at 3 and 6 months. RESULTS The longitudinal analysis showed that PASI improved from a median value of 24.1 at baseline to 2.0 at 6-months and this was also true for BSA (from 23.0 to 2.0) and DLQI (from 24.0 to 2.5) (all p<0.001). At 6-months, PASI75, PASI90 and PASI100 were 95.5%, 59.1% and 16%, respectively. The PSO improvement related with the increase of DLQI (∆PASI vs. ∆DLQI, r=0.77, p<0.001). No clinically relevant adverse events were observed. CONCLUSIONS This study demonstrates the effectiveness and safety of Guselkumab on PSO in real world and shows that the reduction of PSO severity due to the drug is directly related with the improvement of quality of life in this patient population.
Collapse
Affiliation(s)
- G Malara
- Dermatology Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" of Reggio Calabria, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Campanati A, Bianchelli T, Gesuita R, Foti C, Malara G, Micali G, Amerio P, Rongioletti F, Corazza M, Patrizi A, Peris K, Pimpinelli N, Parodi A, Fargnoli MC, Cannavo SP, Pigatto P, Pellacani G, Ferrucci SM, Argenziano G, Cusano F, Fabbrocini G, Stingeni L, Potenza MC, Romanelli M, Bianchi L, Offidani A. Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study. Arch Dermatol Res 2021; 314:593-603. [PMID: 34100126 PMCID: PMC9232418 DOI: 10.1007/s00403-021-02243-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Revised: 02/15/2021] [Accepted: 03/18/2021] [Indexed: 12/03/2022]
Abstract
Adult atopic dermatitis (adult AD) is a systemic inflammatory disorder, whose relationship with immune-allergic and metabolic comorbidities is not well established yet. Moreover, treatment of mild-to-moderate and severe atopic dermatitis needs standardization among clinicians. The aim of this study was to evaluate the distribution of comorbidities, including metabolic abnormalities, rhinitis, conjunctivitis, asthma, alopecia and sleep disturbance, according to severity of adult AD, and describe treatments most commonly used by Italian dermatologists. Retrospective, observational, nationwide study of adult patients over a 2-year period was performed. Clinical and laboratory data were obtained through review of medical records of patients aged ≥ 18 years, followed in 23 Italian National reference centres for atopic dermatitis between September 2016 and September 2018. The main measurements evaluated were disease severity, atopic and metabolic comorbidities, treatment type and duration. Six-hundred and eighty-four adult patients with AD were included into the study. Atopic, but not metabolic conditions, except for hypertension, were significantly associated with having moderate-to-severe AD in young adult patients. Disease duration was significantly associated with disease severity. Oral corticosteroids and cyclosporine were the most widely used immunosuppressant. Our study seems confirm the close relationship between adult AD and other atopic conditions, further long-term cohort studies on patients affected by adult AD need to be performed to evaluate the complex relationship between adult AD disease severity and metabolic comorbidities.
Collapse
Affiliation(s)
- A Campanati
- Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche University, Ancona, Italy
| | - T Bianchelli
- Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche University, Ancona, Italy
| | - R Gesuita
- Centre of Epidemiology and Biostatistics, Polytechnic Marche University, Ancona, Italy
| | - C Foti
- Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, Bari, Italy
| | - G Malara
- Department of Dermatology Grande, Ospedale Metropolitano "Bianchi Melacrino Morelli", Reggio Calabria, Italy
| | - G Micali
- Dermatology Clinic, University of Catania, PO G. Rodolico, AOU Policlinico-Vittorio Emanuele, Catania, Italy
| | - P Amerio
- Department of Medicine and Aging Science, Dermatology Unit, University G.D'Annunzio Chieti, Chieti, Italy
| | | | - M Corazza
- Department of Medical Sciences, Dermatology Unit, University of Ferrara, Ferrara, Italy
| | - A Patrizi
- Department of Experimental, Diagnostic and Specialty Medicine, Division of Dermatology, University of Bologna, Bologna, Italy.
| | - K Peris
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Dermatologia, Rome, Italy.,Sezione di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy.,Oncologia Medica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - N Pimpinelli
- Department Health Science Section of Dermatology, University of Florence, Florence, Italy
| | - A Parodi
- Dermatology Clinic, Ospedale Policlinico San Martino, Largo R. Benzi, 10, 16132, Genoa, Italy
| | - M C Fargnoli
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - S P Cannavo
- Dermatology Unit, University Hospital Policlinico "G. Martino", Messina, Italy
| | - P Pigatto
- Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
| | - G Pellacani
- Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Science With Interest Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - S M Ferrucci
- Department of Physiopathology and Transplantation, Università Degli Studi Di Milano, Milan, Italy.,Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Pace, 9, 20122, Milan, Italy
| | - G Argenziano
- Dermatology Unit, University of Campania, Naples, Italy
| | - F Cusano
- Unit of Dermatology, G. Rummo Hospital, Benevento, Italy
| | - G Fabbrocini
- Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Naples, Italy
| | - L Stingeni
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | - M C Potenza
- Dermatology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome - Polo Pontino, Rome, Italy
| | - M Romanelli
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - L Bianchi
- Dermatology Unit, Policlinico Tor Vergata Rome, University of Rome Tor Vergata, Rome, Italy
| | - A Offidani
- Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche University, Ancona, Italy
| | | |
Collapse
|
6
|
Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G, Offidani A, Ferrucci SM, Amoruso GF, Rossi M, Stingeni L, Malara G, Grieco T, Foti C, Gattoni M, Loi C, Iannone M, Talamonti M, Stinco G, Rongioletti F, Pigatto PD, Cristaudo A, Nettis E, Corazza M, Guarneri F, Amerio P, Esposito M, Belloni Fortina A, Potenza C, Fabbrocini G. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 2021; 35:958-964. [PMID: 33332697 DOI: 10.1111/jdv.17094] [Citation(s) in RCA: 55] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Accepted: 11/20/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. OBJECTIVES A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. METHODS Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. RESULTS Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. CONCLUSIONS Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.
Collapse
Affiliation(s)
- C Patruno
- Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - M Napolitano
- Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
| | - G Argenziano
- Dermatology Unit, University of Campania, Naples, Italy
| | - K Peris
- Dermatology, University of the Sacred Heart, Rome, Italy.,Fondazione Policlinico Universitario A.Gemelli, IRCCS, Rome, Italy
| | - M Ortoncelli
- Dermatology Clinic, University of Turin, Turin, Italy
| | - G Girolomoni
- Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy
| | - A Offidani
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - S M Ferrucci
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - G F Amoruso
- AO Cosenza, UOC Dermatologia, Cosenza, Italy
| | - M Rossi
- UO Dermatologia, ASST Spedali Civili di Brescia, Brescia, Italy
| | - L Stingeni
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | - G Malara
- Struttura Complessa di Dermatologia, Grande Ospedale Metropolitano 'Bianchi Melacrino Morelli', Reggio Calabria, Italy
| | - T Grieco
- Dermatology Unit, Sapienza University of Rome, Rome, Italy
| | - C Foti
- Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy
| | - M Gattoni
- Dermatologic Department, S. Andrea Hospital Vercelli, Vercelli, Italy
| | - C Loi
- Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - M Iannone
- Department of Dermatology, University of Pisa, Pisa, Italy
| | - M Talamonti
- Dermatology Unit, Policlinico Tor Vergata, Department of Systemic Medicine, Tor Vergata University of Rome, Rome, Italy
| | - G Stinco
- Department of Medicine, Institute of Dermatology, University of Udine, Udine, Italy
| | - F Rongioletti
- Unit of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
| | - P D Pigatto
- Department of Medical, Surgical and Odontoiatric Science, IRCCS Ospedale Ortopedico Galeazzi, Milano, Italy
| | - A Cristaudo
- San Gallicano Dermatologic Institute IRCCS, Rome, Italy
| | - E Nettis
- Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy
| | - M Corazza
- Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| | - F Guarneri
- Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Messina, Italy
| | - P Amerio
- Dermatologic Clinic, SS. Annunziata Hospital, Chieti, Italy
| | - M Esposito
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - A Belloni Fortina
- Unit of Dermatology, Department of Medicine DIMED, University of Padua, Padua, Italy
| | - C Potenza
- Dermatology Unit 'Daniele Innocenzi', Department of MEDICO-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, Italy
| | - G Fabbrocini
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy
| | | |
Collapse
|
7
|
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Peccianti C, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavo SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Stingeni L, Caruso C, Argenziano G. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J DERMATOL TREAT 2020; 33:1146-1149. [DOI: 10.1080/09546634.2020.1773379] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- M. C. Fargnoli
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - M. Esposito
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - S. Ferrucci
- Unit of Dermatology, Fondazione IRCCS Ca’ Grande Ospedale Maggiore Policlinico, Milan, Italy
| | - G. Girolomoni
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - A. Offidani
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - A. Patrizi
- Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - K. Peris
- Institute of Dermatology, Catholic University, Rome, Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - A. Costanzo
- Dermatology Unit, Department of Biomedical Sciences, Humanitas University and Humanitas Clinical and Research Center, Rozzano, Italy
| | - G. Malara
- Dermatology Department, Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Reggio Calabria, Italy
| | - G. Pellacani
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
| | - M. Romanelli
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - P. Amerio
- Department of Medicine and Aging Science, Dermatologic Clinic, G. D’Annunzio University, Chieti, Italy
| | - A. Cristaudo
- Unit of Dermatology, San Gallicano Dermatological Institute-IRCCS, Rome, Italy
| | - M. L. Flori
- Dermatology Section, Department of Clinical Medicine and Immunological Science, University of Siena, Hospital S. Maria Alle Scotte, Siena, Italy
| | - A. Motolese
- Department of Dermatology, IRCCS Santa Maria Nuova, Reggio Emilia, Italy
| | - P. Betto
- Department of Dermatology, ULSS8 Berica, Vicenza, Italy
| | - C. Patruno
- Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - P. Pigatto
- Department of Biomedical, Surgical and Dental Sciences, Clinical Dermatology, IRCCS Galeazzi Orthopaedic Institute, University of Milan, Milan, Italy
| | - C. Peccianti
- Unit of Dermatology, Ospedale Della Misericordia, Grosseto, Italy
| | - G. Stinco
- Department of Medicine, Institute of Dermatology, University of Udine, Udine, Italy
| | - I. Zalaudek
- Dermatology Clinic, Hospital Maggiore of Trieste, Trieste, Italy
| | - L. Bianchi
- Department of Dermatology, University of Tor Vergata, Rome, Italy
| | - V. Boccaletti
- Section of Dermatology, Department of Clinical and Experimental Medicine, University Hospital, Parma
| | - S. P. Cannavo
- Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - F. Cusano
- Dermatology Unit, Gaetano Rummo Hospital Benevento, Benevento, Italy
| | - S. Lembo
- Unit of Dermatology, Hospital Santa Maria Incoronata Dell’Olmo, Cava De’ Tirreni, University Hospital San Giovanni di Dio e Ruggi di Salerno, Salerno, Italy
| | - R. Mozzillo
- Dermatology and Venereology, San Gennaro Hospital, Naples, Italy
| | - R. Gallo
- Dermatology Section, Department of Health Science, University of Genoa, Polyclinic Hospital San Martino, Genoa, Italy
| | - C. Potenza
- Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome, Rome, Italy
| | - F. Rongioletti
- Section of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
| | - R. Tiberio
- Department of Health Science, University of Eastern Piedmont, Novara, Italy
| | - T. Grieco
- Unit of Dermatology Clinic Umberto I, Sapienza University of Rome, Rome, Italy
| | - G. Micali
- Unit of Dermatology Clinic, University of Catania, Catania, Italy
| | - S. Persechino
- Unit of Dermatology, Sant’Andrea Hospital, NESMOS Department, Sapienza University of Rome, Rome, Italy
| | - M. Pettinato
- Unit of Dermatology, University Hospital, Policlinico Vittorio Emanuele, Catania, Italy
| | - S. Pucci
- Allergology, Hospital of Civitanova Marche, Civitanova Marche, Italy
| | - L. Stingeni
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | - C. Caruso
- Unit of Allergy, Fondazione Policlinico Universitario A. Gemelli, IRCCS Rome, Italy
| | - G. Argenziano
- Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy
| |
Collapse
|
8
|
Gisondi P, Bellinato F, Conti A, Dapavo P, Piaserico S, De Simone C, Chiricozzi A, Dattola A, Malagoli P, Malara G, Campanati A, Burlando M, Esposito M, Gallo L, Girolomoni G. Consensus on the place in therapy of TNF‐α inhibitors in the treatment of patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2020; 34:e470-e472. [DOI: 10.1111/jdv.16380] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Accepted: 03/10/2020] [Indexed: 01/13/2023]
Affiliation(s)
- P. Gisondi
- Department of Medicine Section of Dermatology and Venereology University of Verona Verona Italy
| | - F. Bellinato
- Department of Medicine Section of Dermatology and Venereology University of Verona Verona Italy
| | - A. Conti
- Department of Surgical Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative Medicine Dermatology Unit University of Modena and Reggio Emilia Modena Italy
| | - P. Dapavo
- Department of Biomedical Science and Human Oncology Second Dermatologic ClinicUniversity of Turin Turin Italy
| | - S. Piaserico
- Section of Dermatology Department of Medicine University of Padua Padova Italy
| | - C. De Simone
- Institute of Dermatology Catholic University Rome Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
| | - A. Chiricozzi
- Institute of Dermatology Catholic University Rome Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
| | - A. Dattola
- Department of Dermatology University of Rome Tor Vergata Rome Italy
| | - P. Malagoli
- Dermatology Unit Azienda Ospedaliera San Donato Milanese Milan Italy
| | - G. Malara
- Dermatology Unit Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy
| | - A. Campanati
- Department of Clinical and Molecular Sciences Dermatological Clinic Polytechnic Marche University Ancona Italy
| | - M. Burlando
- Section of Dermatology Department of Health Sciences San Martino University Hospital IRCCS University of Genoa Genoa Italy
| | - M. Esposito
- Dermatology Unit Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy
| | - L. Gallo
- Section of Dermatology Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy
| | - G. Girolomoni
- Department of Medicine Section of Dermatology and Venereology University of Verona Verona Italy
| |
Collapse
|
9
|
Damiani G, Calzavara‐Pinton P, Stingeni L, Hansel K, Cusano F, Pigatto PD, Agostinelli D, Albertazzi D, Angelini G, Angerosa F, Arigliano P, Assalve D, Ayala F, Barbagallo T, Belloni‐Fortina A, Berta M, Biale C, Bianchi L, Biasini I, Boccaletti V, Bonamonte D, Borghi A, Bragazzi N, Brambilla L, Bressan M, Brunasso A, Bruni F, Bruni P, Caccavale S, Calogiuri G, Cannavò S, Carugno A, Cataldi I, Chiarelli G, Cirla A, Corazza M, Cossutta M, Cova L, Cristaudo A, Cusano F, Danese P, Dal Canton M, De Pità O, De Salvo P, Donini M, Fantini F, Ferrucci S, Flori M, Fontana E, Foti C, Francalci S, Frasin L, Gallo R, Gasparini G, Gola M, Gravante M, Guarnieri F, Guastaferro D, Ingordo V, Lauriola M, Leghissa P, Lisi P, Lombardi P, Lorenzini M, Malara G, Magrini L, Marone G, Martina E, Mascagni P, Matteini Chiari M, Meligeni L, Melino M, Miccio L, Milanesi N, Molinu A, Monfrecola G, Morelli P, Motolese A, Musumeci M, Naldi L, Napolitano M, Nasca M, Pacifico A, Paganini P, Papini M, Pasolini G, Patruno C, Pellegrino M, Peroni A, Peserico A, Piras V, Pugliese A, Raponi F, Raviolo P, Rebora A, Recchia G, Riva F, Romita P, Rossi M, Ruggieri M, Saggiorato F, Sartorelli P, Schena D, Schettino A, Spanò G, Stinchi C, Tasin L, Tramontana M, Taddei L, Valsecchi R, Russo F, Vascellaro A, Venturini M, Vincenzi C, Virgili A, Zucca M. Italian guidelines for therapy of atopic dermatitis—Adapted from consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther 2019; 32:e13121. [DOI: 10.1111/dth.13121] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Revised: 10/04/2019] [Accepted: 10/11/2019] [Indexed: 12/13/2022]
Affiliation(s)
- Giovanni Damiani
- Department of Biomedical, Surgical, and Dental Sciences Unit of DermatologyUniversity of Milan Milan Italy
- IRCCS Istituto Ortopedico Galeazzi Milan Italy
- Young Dermatologists Italian NetworkGISED Bergamo Italy
- Department of DermatologyCase Western Reserve University Cleveland Ohio
| | | | - Luca Stingeni
- Section of Dermatology, Department of MedicineUniversity of Perugia Perugia Italy
| | - Katharina Hansel
- Section of Dermatology, Department of MedicineUniversity of Perugia Perugia Italy
| | | | - Paolo D.M. Pigatto
- Department of Biomedical, Surgical, and Dental Sciences Unit of DermatologyUniversity of Milan Milan Italy
- IRCCS Istituto Ortopedico Galeazzi Milan Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Sirna R, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavò SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Savi E, Stingeni L, Romano A, Argenziano G. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J DERMATOL TREAT 2019; 32:507-513. [DOI: 10.1080/09546634.2019.1682503] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- M. C. Fargnoli
- Dermatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - M. Esposito
- Dermatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - S. Ferrucci
- Unit of Dermatology, Fondazione IRCCS Ca’ Grande Ospedale Maggiore Policlinico, Milan, Italy
| | - G. Girolomoni
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - A. Offidani
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - A. Patrizi
- Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - K. Peris
- Institute of Dermatology, Catholic University, Rome, Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - A. Costanzo
- Dermatology Unit, Department of Biomedical Sciences, Humanitas University and Humanitas Clinical and Research Center, Rozzano, Italy
| | - G. Malara
- Dermatology Department, Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Reggio Calabria, Italy
| | - G. Pellacani
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
| | - M. Romanelli
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - P. Amerio
- Department of Medicine and Aging Science, Dermatologic Clinic, G. D’Annunzio University, Chieti, Italy
| | - A. Cristaudo
- Unit of Dermatology, San Gallicano Dermatological Institute-IRCCS, Rome, Italy
| | - M. L. Flori
- Dermatology Section, Department of Clinical Medicine and Immunological Science, University of Siena, Hospital S. Maria Alle Scotte, Siena, Italy
| | - A. Motolese
- Department of Dermatology, Macchi Hospital, Varese, Italy
| | - P. Betto
- Department of Dermatology, Ospedale San Bortolo, ULSS8 Berica, Vicenza, Italy
| | - C. Patruno
- Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - P. Pigatto
- Department of Biomedical, Surgical and Dental Sciences, Clinical Dermatology, IRCCS Galeazzi Orthopaedic Institute, University of Milan, Milan, Italy
| | - R. Sirna
- Unit of Dermatology, Ospedale Della Misericordia, Grosseto, Italy
| | - G. Stinco
- Department of Medicine, Institute of Dermatology, University of Udine, Udine, Italy
| | - I. Zalaudek
- Dermatology Clinic, Hospital Maggiore of Trieste, Trieste, Italy
| | - L. Bianchi
- Department of Dermatology, University of Tor Vergata, Rome, Italy
| | - V. Boccaletti
- Section of Dermatology, Department of Clinical and Experimental Medicine, University Hospital, Parma
| | - S. P. Cannavò
- Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - F. Cusano
- Dermatology Unit, Gaetano Rummo Hospital Benevento, Benevento, Italy
| | - S. Lembo
- Unit of Dermatology, University Hospital San Giovanni di Dio e Ruggi di Salerno, Hospital Santa Maria Incoronata Dell’Olmo, Cava De’ Tirreni, Salerno, Italy
| | - R. Mozzillo
- Dermatology and Venereology, “San Gennaro” Hospital, Naples, Italy
| | - R. Gallo
- Dermatology Section, Department of Health Science, University of Genoa, Polyclinic Hospital San Martino, Genoa, Italy
| | - C. Potenza
- Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome - Polo Pontino, Rome, Italy
| | - F. Rongioletti
- Section of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
| | - R. Tiberio
- Department of Health Science, University of Eastern Piedmont, Novara, Italy
| | - T. Grieco
- Dermatology Clinic Umberto I, Sapienza University of Rome, Rome, Italy
| | - G. Micali
- Dermatology Clinic, University of Catania, Catania, Italy
| | - S. Persechino
- Dermatology Unit, Sant’Andrea Hospital, NESMOS Department, Sapienza University of Rome, Rome, Italy
| | - M. Pettinato
- Unit of Dermatology, University Hospital, Policlinico Vittorio Emanuele, Catania, Italy
| | - S. Pucci
- Allergology, Hospital of Civitanova Marche, Civitanova Marche, Italy
| | - E. Savi
- Unit of Dermatology, Hospital Guglielmo da Saliceto, Piacenza, Italy
| | - L. Stingeni
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | - A. Romano
- Allergology Unit, Columbus Presidium, Catholic University, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - G. Argenziano
- Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy
| | | |
Collapse
|
11
|
Conti A, Peccerillo F, Amerio P, Balato A, Bardazzi F, Bianchi L, Burlando M, Cannavò S, Chiricozzi A, Dapavo P, De Simone C, Fargnoli M, Gambardella A, Gisondi P, Malagoli P, Malara G, Mugheddu C, Offidani A, Piaserico S, Prignano F, Stingeni L, Pellacani G. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol 2019; 180:1547-1548. [DOI: 10.1111/bjd.17580] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- A. Conti
- Department of Dermatology University of Modena and Reggio Emilia Modena Italy
| | - F. Peccerillo
- Department of Dermatology University of Modena and Reggio Emilia Modena Italy
| | - P. Amerio
- Department of Medicine and Aging Science Dermatologic Clinic, G. D'Annunzio University Chieti Italy
| | - A. Balato
- Department of Dermatology University of Naples Federico II Naples Italy
| | - F. Bardazzi
- Department of Specialized, Clinical and Experimental Medicine Division of Dermatology University of Bologna Bologna Italy
| | - L. Bianchi
- Department of Dermatology University of Rome Tor Vergata Rome Italy
| | - M. Burlando
- Section of Dermatology University of Genoa San Martino Polyclinic Hospital Genoa Italy
| | - S.P. Cannavò
- Department of Clinical and Experimental Medicine – Dermatology University of Messina Messina Italy
| | - A. Chiricozzi
- Department of Dermatology University of Pisa Pisa Italy
| | - P. Dapavo
- Department of Biomedical Science and Human Oncology Second Dermatologic Clinic University of Turin Turin Italy
| | - C. De Simone
- Department of Dermatology Catholic University of the Sacred Heart Rome Italy
| | - M.C. Fargnoli
- Department of Dermatology University of L'Aquila L'Aquila Italy
| | | | - P. Gisondi
- Department of Medicine Section of Dermatology and Venereology University of Verona Verona Italy
| | - P. Malagoli
- Dermatology Unit Azienda Ospedaliera San Donato Milanese Milan Italy
| | - G. Malara
- Dermatology Department Grande Ospedale Metropolitano Bianchi Melacrino Morelli 89124 Reggio Calabria Italy
| | - C. Mugheddu
- Department of Medical Sciences and Public Health Section of Dermatology University of Cagliari Cagliari Italy
| | - A.M. Offidani
- Department of Clinical and Molecular Sciences Dermatology Unit Polytechnic Marche University Ancona Italy
| | - S. Piaserico
- Department of Dermatology University of Padua Padova Italy
| | - F. Prignano
- Department of Dermatology University of Florence Firenze Italy
| | - L. Stingeni
- Department of Medicine Section of Clinical, Allergological and Venereological Dermatology University of Perugia Perugia Italy
| | - G. Pellacani
- Department of Dermatology University of Modena and Reggio Emilia Modena Italy
| |
Collapse
|
12
|
Peris K, Lo Schiavo A, Fabbrocini G, Dini V, Patrizi A, Fusano M, Bianchi L, Guanziroli E, Guarneri C, Parodi A, Bertoldi A, Musumeci ML, Offidani A, Rongioletti F, Pistone G, Malara G, Potenza C, Casari A, Franchi C, Ardigò M, Cusano F, Stingeni L, Amerio P, Mancini LL, Prignano F, Deboli T, Gualberti G, Saragaglia V, Bettoli V. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019; 33:766-773. [PMID: 30633405 PMCID: PMC6593467 DOI: 10.1111/jdv.15425] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Accepted: 12/03/2018] [Indexed: 11/28/2022]
Abstract
BACKGROUND Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease characterized by painful inflamed nodules, recurrent abscesses and fistulas located in apocrine gland-bearing body sites. The negative impact of HS on patient's quality of life (QoL) has been reported to be greater than other dermatologic conditions as psoriasis and atopic eczema, and its improvement is an important goal in disease management. Nowadays, there are no specific validated QoL instruments available for HS and generic dermatologic questionnaires are used. OBJECTIVE The objective of this study was to demonstrate the validity, reliability and responsiveness of HIDRAdisk, a new innovative tool designed for rapid assessment of HS burden and, at the same time, an intuitive graphic visualization of the measurement outcome. METHODS A multicentre, longitudinal, observational study was conducted to validate the HIDRAdisk compared with other validated questionnaires [Skindex-16, Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment-General Health (WPAI:GH)] and to evaluate its correlation with disease severity in Italian patients with any degree of HS severity, as measured by Hurley stage and HS Physician Global Assessment (HS-PGA). RESULTS A total of 140 patients (59% women; mean age 34.9 ± 11.0 years) were enrolled in 27 dermatologic centres. HIDRAdisk showed a strong correlation with Skindex-16 and DLQI, and a good one with WPAI:GH (correlation coefficient: 0.7568, 0.6651 and 0.5947, respectively) and a statistically significant correlation with both Hurley stage and HS-PGA. Very good internal consistency (Cronbach coefficient >0.80; intraclass correlation coefficient >0.6), with correlation between the 10 items, good test-retest reliability (Spearman correlation coefficient, 0.8331; P < 0.0001) and responsiveness to changes were demonstrated. CONCLUSION Our study shows that HIDRAdisk, a short and innovative visual HS QoL instrument, has been psychometrically validated in Italian language and it may help improve the management of HS once implemented in routine clinical practice.
Collapse
Affiliation(s)
- K Peris
- Istituto di Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma - Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Lo Schiavo
- Unità di Dermatologia, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - G Fabbrocini
- U.O.C. di Dermatologia- Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Naples, Italy
| | - V Dini
- U.O. Dermatologia, Università di Pisa, Pisa, Italy
| | - A Patrizi
- Dermatologia, DIMES (Dipartimento di Medicina clinica Specialistica e Sperimentale), Università di Bologna, Bologna, Italy
| | - M Fusano
- ASST Spedali Civili of Brescia, U.O. Dermatologia e Venereologia, Università di Brescia, Brescia, Italy
| | - L Bianchi
- Unità Operativa di Dermatologia, Policlinico Tor Vergata, Università degli studi di Roma Tor Vergata, Rome, Italy
| | - E Guanziroli
- Dipartimento di Fisiopatologia, IRCCS Fondazione Ca' Granda - Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
| | - C Guarneri
- Dipartimento di Scienze Biomediche e Dentali e Imaging Morfofunzionale, Unità di Dermatologia, Università di Messina, Messina, Italy
| | - A Parodi
- DiSSal Sezione di Dermatologia, Università di Genova, Ospedale-Policlinico San Martino, Genoa, Italy
| | - A Bertoldi
- Dipartimento di Dermatologia, Ospedale "Santi Giovanni e Paolo", Venice, Italy
| | - M L Musumeci
- Dermatology Clinic, P.O. G. Rodolico, A.O.U. Policlinico-Vittorio Emanuele, Catania, Italy
| | - A Offidani
- SOD Clinica di Dermatologia, Università Politecnica delle Marche, Azienda Ospedaliera Universitaria, Ancona, Italy
| | - F Rongioletti
- Clinica Dermatologica, Dipartimento di scienze Mediche e Salute Pubblica, Università di Cagliari, Cagliari, Italy
| | - G Pistone
- Dipartimento Di.Bi. MIS, U.O.C. di Dermatologia e MTS, A.O.U.P "Paolo Giaccone", Palermo, Italy
| | - G Malara
- Struttura Complessa presso la UOC di Dermatologia GOM "Bianchi Melacrino Morelli", Reggio Calabria, Italy
| | - C Potenza
- Facoltà di Farmacia e Medicina, U.O.C. di Dermatologia "Daniele Innocenzi", Università degli Studi di Roma "Sapienza", Polo Pontino, Italy
| | - A Casari
- Clinica Dermatologica, Policlinico di Modena, Modena, Italy
| | - C Franchi
- UO dermatologia, IRCCS Galeazzi, Milan, Italy
| | - M Ardigò
- U.O.C. di Dermatologia Clinica, IFO-San Gallicano, IRCCS, Rome, Italy
| | - F Cusano
- U.O.C. di Dermatologia, A.O. Gaetano Rummo, Benevento, Italy
| | - L Stingeni
- Sezione di Dermatologia Clinica, Allergologica e Venereologica, Dipartimento di Medicina, Università di Perugia, Perugia, Italy
| | - P Amerio
- Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G. d'Annunzio, Chieti, Italy
| | - L L Mancini
- Unità di Dermatologia, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
| | - F Prignano
- Clinica Dermatologica - ASF Dipartimento di Chirurgia e Medicina Translazionale, Ospedale Piero Palagi, Università di Firenze, Florence, Italy
| | - T Deboli
- Dermatologia, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy
| | | | | | - V Bettoli
- Dipartimento di Medicina Clinica e Specialistica, U.O. di Dermatologia, A.O.U. di Ferrara, Ferrara, Italy
| |
Collapse
|
13
|
Costanzo A, Bianchi L, Flori M, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G. HLA-Cw6 allele and efficacy of secukinumab. Br J Dermatol 2018. [DOI: 10.1111/bjd.17218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Costanzo A, Bianchi L, Flori M, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G. HLA-Cw6 等位基因和苏金单抗的疗效. Br J Dermatol 2018. [DOI: 10.1111/bjd.17232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Costanzo A, Bianchi L, Flori M, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G. Secukinumab shows high efficacy irrespective of HLA-Cw6
status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol 2018; 179:1072-1080. [DOI: 10.1111/bjd.16705] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/06/2018] [Indexed: 12/16/2022]
Affiliation(s)
- A. Costanzo
- Dermatology Unit; Department of Biomedical Sciences; Humanitas University; Via Alessandro Manzoni 113 Rozzano-Milan 20089 Italy
- Skin Pathology Laboratory; IRCCS Istituto Clinico Humanitas; Via Alessandro Manzoni 113 Rozzano-Milan 20089 Italy
| | - L. Bianchi
- Dermatology; Department of Systems Medicine; Policlinico di Tor Vergata; University of Rome Tor Vergata; Viale Oxford 81 Rome 00133 Italy
| | - M.L. Flori
- Dermatology Section; Department of Clinical Medicine and Immunological Science; University of Siena; Hospital S. Maria alle Scotte; viale Bracci Siena Italy
| | - G. Malara
- Dermatology Department; Grande Ospedale Metrapolitano; Bianchi Melacrino Morelli; 89124 Reggio Calabria Italy
| | - L. Stingeni
- Section of Clinical, Allergological and Venereological Dermatology; Department of Medicine; University of Perugia; Piazza Menghini 1 Perugia 06129 Italy
| | - M. Bartezaghi
- Novartis Farma S.p.A.; Via Saronnino Origgio VA 21042 Italy
| | - L. Carraro
- Novartis Farma S.p.A.; Via Saronnino Origgio VA 21042 Italy
| | - G. Castellino
- Novartis Farma S.p.A.; Via Saronnino Origgio VA 21042 Italy
| | | |
Collapse
|
16
|
Gisondi P, Altomare G, Ayala F, Conti A, Dapavo P, De Simone C, Foti C, Idolazzi L, Lubrano E, Malara G, Marchesoni A, Olivieri I, Parodi A, Peris K, Piaserico S, Salvarani C, Scarpa R, Girolomoni G. Consensus on the management of patients with psoriatic arthritis in a dermatology setting. J Eur Acad Dermatol Venereol 2018; 32:515-528. [PMID: 29220551 DOI: 10.1111/jdv.14741] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2017] [Accepted: 11/22/2017] [Indexed: 12/13/2022]
Abstract
BACKGROUND Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis (PsO). Early diagnosis and prompt therapeutic intervention are crucial for limiting PsA progression and prevention of disability. Dermatologists are in a privileged position to detect early PsA. The management of patients with PsA in the dermatology setting is widely variable. OBJECTIVE To provide practical recommendations for the management of patients with PsA in the dermatology setting including early diagnosis and treatment. METHODS A consensus document was written by an expert panel composed by dermatologists (n = 12) and rheumatologists (n = 6). Eleven highly relevant questions were selected and elaborated with answers/statements based on a narrative literature review. The resulting document was discussed in a face-to-face meeting adopting a nominal group technique to reach consensus (i.e. 100% agreement) using the Delphi method. RESULTS A consensus was achieved in defining the following: the clinical characteristics differentiating inflammatory and non-inflammatory signs and symptoms of joint disease; the most important differential diagnoses of PsA in clinical practice; the most useful screening questionnaires, serum laboratory tests and imaging techniques for the detection of early PsA; the criteria for dermatologist to refer patients with PsO to rheumatologist; the criteria for the diagnosis of PsA; the selection of the indices that the dermatologist could use for measuring the activity and severity of PsA in clinical practice; when systemic steroids and/or intra-articular steroid injections are indicated in the treatment of PsA. Finally, systemic treatments including synthetic and biologic disease-modifying antirheumatic drugs to be considered for the treatment of PsA have been reported. CONCLUSIONS The implementations of these practical recommendations could be very helpful for the management of patients with PsA in the dermatology setting including early diagnosis and treatment.
Collapse
Affiliation(s)
- P Gisondi
- Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy
| | - G Altomare
- I.R.C.C.S Istituto Ortopedico Galeazzi, Division of Dermatology and Venereology, University of Milan, Milan, Italy
| | - F Ayala
- Department of Dermatology, University of Naples Federico II, Naples, Italy
| | - A Conti
- Department of Head and Neck Surgery, Section of Dermatology, Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy
| | - P Dapavo
- Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy
| | - C De Simone
- Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy
| | - C Foti
- Department of Biomedical Science and Human Oncology, Section of Dermatology, University of Bari, Bari, Italy
| | - L Idolazzi
- Department of Medicine, Section of Rheumatology, University of Verona, Verona, Italy
| | - E Lubrano
- Dipartimento di Medicina e Scienze della Salute "Vincenzo Tiberio", Università degli Studi del Molise, Campobasso, Italy
| | - G Malara
- Unit of Dermatology, Azienda Ospedaliera Papardo, Messina, Italy
| | - A Marchesoni
- Department of Rheumatology, ASST Gaetano Pini-CTO, Milano, Italy
| | - I Olivieri
- Division of Rheumatology, Azienda Ospedaliera San Carlo, Potenza, Italy
| | - A Parodi
- Section of Dermatology, University of Genoa, Genoa, Italy
| | - K Peris
- Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy
| | - S Piaserico
- Department of Medicine, Section of Dermatology, University of Padua, Padua, Italy
| | - C Salvarani
- Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Modena, Reggio Emilia, Italy
| | - R Scarpa
- Department of Medicine, Section of Rheumatology, University of Naples Federico II, Naples, Italy
| | - G Girolomoni
- Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy
| |
Collapse
|
17
|
Vena G, Cassano N, Agnusdei C, Bellini M, Calabretta S, Centofanti S, Cervadoro G, Coviello C, Curia S, Dattola S, De Caro C, Del Brocco L, Donato L, Favero L, Ferrari A, Gianfaldoni R, Liguori G, Loconsole F, Lopreiato R, Malara G, Massimino S, Nannipieri A, Pettinato M, Postiglione D, Postorino C, Pronesti' M, Provenzano E, Guerra AP, Ricciuti F, Ruggiero G, Scudero A, Spitaleri S, Armati FT, Valenti G, Vernaci R, Verrina F, Zagni G, Zappala' F. Treatment of Psoriasis Vulgaris with Calcipotriol Betamethasone Dipropionate Combination Followed by Calcipotriol and Assessment of the Adjuvant Basic Use of Urea-Based Emollients. EUR J INFLAMM 2016. [DOI: 10.1177/1721727x0500300108] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
A new combination product containing betamethasone dipropionate and calcipotriol (Dovobet® ointment) has been proven very effective and well tolerated in patients with psoriasis vulgaris. Emollients are adjunctive modalities commonly used in psoriasis; however, their actual role in combination with topical drugs as well as well as their compatibility with these drugs have not been well elucidated. In 313 adult patients with psoriasis vulgaris, we studied the efficacy and tolerability of treatment with Dovobet® ointment combined with urea-based emollients (Excipial U®) for 4 weeks, followed by treatment with calcipotriol (Daivonex®) either alone (group A) or combined with urea-containing emollients (Excipial U®, group B) for 8 weeks. Clinical evaluations were performed at baseline, at 4 and 12 weeks, assessing the clinical score for erythema, scaling, infiltration and pruritus, graded on the basis of a 5-point scale. After the initial 4-week treatment, a significant improvement of all clinical parameters was observed (p<0.05). Overall, clinical results improved further during the maintenance treatment phase; significant changes (p<0.05) were observed in each group. Most patients considered treatment efficacy positively at both 4 weeks and 12 weeks. Interestingly, at the end of the study, a greater percentage of patients in group B than in group A judged the efficacy as excellent. Treatment was very well tolerated. Only two patients complained of mild and transient burning sensation during the first days of treatment. The results of this study confirm the great efficacy and tolerability of sequential treatment with Dovobet®, and Daivonex® in psoriasis vulgaris and show the enhanced acceptability of this treatment associated with urea-based emollients.
Collapse
Affiliation(s)
- G.A. Vena
- 2nd Unit of Dermatology - MIDIM Department, University of Bari, Italy
| | - N. Cassano
- 2nd Unit of Dermatology - MIDIM Department, University of Bari, Italy
- Istituto Dermopatico dell'Immacolata, Rome, Italy
| | - C.P. Agnusdei
- Italian Group for the Study of Emollients in Psoriasis
| | - M. Bellini
- Italian Group for the Study of Emollients in Psoriasis
| | - S. Calabretta
- Italian Group for the Study of Emollients in Psoriasis
| | - S. Centofanti
- Italian Group for the Study of Emollients in Psoriasis
| | - G. Cervadoro
- Italian Group for the Study of Emollients in Psoriasis
| | - C. Coviello
- 2nd Unit of Dermatology - MIDIM Department, University of Bari, Italy
| | - S. Curia
- Italian Group for the Study of Emollients in Psoriasis
| | - S. Dattola
- Italian Group for the Study of Emollients in Psoriasis
| | - C. De Caro
- Italian Group for the Study of Emollients in Psoriasis
| | - L. Del Brocco
- Italian Group for the Study of Emollients in Psoriasis
| | - L. Donato
- Italian Group for the Study of Emollients in Psoriasis
| | - L. Favero
- Italian Group for the Study of Emollients in Psoriasis
| | - A. Ferrari
- Italian Group for the Study of Emollients in Psoriasis
| | | | - G. Liguori
- Italian Group for the Study of Emollients in Psoriasis
| | - F. Loconsole
- 2nd Unit of Dermatology - MIDIM Department, University of Bari, Italy
| | - R. Lopreiato
- Italian Group for the Study of Emollients in Psoriasis
| | - G. Malara
- Italian Group for the Study of Emollients in Psoriasis
| | | | - A. Nannipieri
- Italian Group for the Study of Emollients in Psoriasis
| | - M. Pettinato
- Italian Group for the Study of Emollients in Psoriasis
| | | | - C. Postorino
- Italian Group for the Study of Emollients in Psoriasis
| | | | | | | | - F. Ricciuti
- Italian Group for the Study of Emollients in Psoriasis
| | - G. Ruggiero
- Italian Group for the Study of Emollients in Psoriasis
| | - A. Scudero
- Italian Group for the Study of Emollients in Psoriasis
| | - S. Spitaleri
- Italian Group for the Study of Emollients in Psoriasis
| | | | - G. Valenti
- Italian Group for the Study of Emollients in Psoriasis
| | - R. Vernaci
- Italian Group for the Study of Emollients in Psoriasis
| | - F. Verrina
- Italian Group for the Study of Emollients in Psoriasis
| | - G.F. Zagni
- Italian Group for the Study of Emollients in Psoriasis
| | - F. Zappala'
- Italian Group for the Study of Emollients in Psoriasis
| |
Collapse
|
18
|
Peris K, Calzavara-Pinton PG, Neri L, Girolomoni G, Malara G, Parodi A, Piaserico S, Rossi R, Pellacani G. Italian expert consensus for the management of actinic keratosis in immunocompetent patients. J Eur Acad Dermatol Venereol 2016; 30:1077-84. [PMID: 27060910 DOI: 10.1111/jdv.13648] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Accepted: 01/15/2016] [Indexed: 12/27/2022]
Abstract
Actinic keratosis (AK) is a common skin disease which can potentially progress to invasive squamous cell carcinoma (iSCC). Given that mortality rates and health-care cost associated with iSCC are substantial, the management of AK represents an important public health issue. Several effective lesion-directed and field-directed treatments are available. Ablative procedures (e.g. cryosurgery, excision, laser ablation, curettage alone or with electrodessication) are considered cost-effective options for solitary lesions. Field-directed therapies (e.g. Ingenol Mebutate, imiquimod, PDT, 5-Fluorouracile, diclofenac 3%, 5-FU + Salicylic acid) can be used over large epidermal surfaces and are directed to treat both individual visible lesions and cancerization fields. In order to provide guidance for management choice in clinical practice, several guidelines concerning the diagnosis and treatment of AK have been published in the past decade. However, the introduction of novel therapeutic options requires continuous updates of recommendations and adaptation to national contexts. The present review summarizes the existing evidence and reports the results of a consensus workshop on the management of AK.
Collapse
Affiliation(s)
- K Peris
- Unit of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - P G Calzavara-Pinton
- Department of Clinical and Experimental Science, University of Brescia, Brescia, Italy
| | - L Neri
- Department of Clinical Science and Community Health, University of Milan, Milan, Italy
| | - G Girolomoni
- Unit of Dermatology, University of Verona, Verona, Italy
| | - G Malara
- Unit of Dermatology, AO Papardo, Messina, Italy
| | - A Parodi
- Dermatology Clinic, AO San Martino, University of Genoa, Genoa, Italy
| | - S Piaserico
- Division of Dermatology, Department of Medicine, University of Padua, Padua, Italy
| | - R Rossi
- Division of Dermatology, University of Florence, Florence, Italy
| | - G Pellacani
- Unit of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
19
|
Migliore A, Cusano F, Bianchi G, Malara G, Epis O, De Pità O. MANAGEMENT OF PSORIATIC ARTHRITIS: SHOULD THE INTERACTION BETWEEN DERMATOLOGISTS AND RHEUMATOLOGISTS IN CLINICAL PRACTICE BE INTENSIFIED? J BIOL REG HOMEOS AG 2015; 29:547-561. [PMID: 26403393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Psoriatic arthritis is an inflammatory seronegative spondyloarthropathy that occurs in approximately 25% of patients with psoriasis and is a progressive and severely disabling disease. Most patients have had psoriasis for several years before the development of arthritis or develop the joint and skin condition simultaneously. Given the absence of specific diagnostic test for psoriatic arthritis, clinical findings remain the standard criteria for the diagnosis. Patients with psoriasis presenting to the dermatologist for management of their skin disease may have joint symptoms related or not to psoriatic arthritis and similarly arthritic patients presenting to a rheumatologist for the management of psoriatic arthritis may have skin lesions related or not to psoriasis. In this paper an expert panel of specialist belonging to the Associazione Dermatologi Ospedalieri Italiani (ADOI) and Collegio dei Reumatologi Ospedalieri Italiani (CROI) analysed the international literature and scientific recommendations and also investigated the Italian setting. It has been demonstrated in the literature that a multidisciplinary clinical setting may benefit patients with psoriatic arthritis from both diagnostic and therapeutic points of view. The comparative analysis of the Italian clinical records used by ADOI and CROI have highlighted some substantial differences. Collaboration between the dermatologist and rheumatologist allows for a more complete appreciation of the overall skin and musculoskeletal disease burden, and subsequently leads to a more comprehensive treatment approach.
Collapse
Affiliation(s)
- A Migliore
- U.O. Reumatologia, Ospedale San Pietro, Roma, Italy
| | - F Cusano
- U. O. C. Dermatologia, Azienda Ospedaliera G. Rummo, Benevento, Italy
| | - G Bianchi
- U.O. Reumatologia, ASL3, Azienda Sanitaria Genovese, Genova, Italy
| | - G Malara
- U.O. Dermatologia Ospedale Papardo, Messina Italy
| | - O Epis
- U.O. Reumatologia, Ospedale Niguarda Ca Granda, Milano Italy
| | - O De Pità
- Istituto Dermopatico dellImmacolata, Roma, Italy
| |
Collapse
|
20
|
Gisondi P, Malara G, Ardigò M. The psoriatic patient profile for infliximab. Eur Rev Med Pharmacol Sci 2011; 15:1445-1451. [PMID: 22288305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population worldwide. Psoriasis results from a complex and dynamic interplay between genetic and environmental factors that trigger an excessive inflammatory response in the skin which is driven by several mediators including TNF-alpha. The common form of the disease, termed 'chronic plaque psoriasis' is characterized by erythematous scaly plaques, typically on elbows, knees, scalp and buttocks. Psoriasis does not only affect the skin but also the nails and sometimes it is associated to a form of negative spondyloarthropathy, named the psoriatic arthritis (PsA), which could affect joints, tendons and/or the bone. Moreover, psoriasis is also frequently associated to metabolic comorbidities including obesity, dyslipidemia, diabetes and non alcoholic fatty liver disease. Consequently, psoriasis causes a high degree of morbidity and impairment of quality of life. There is no definite cure for psoriasis although there are treatments which could induce its remission. During the past decade, new very selective biological therapies for the management of psoriasis have been licensed. Biological drugs include TNF-alpha inhibitors (etanercept, infliximab and adalimumab) and ustekinumab which is an anti-IL 2/23 monoclonal antibody. Infliximab is very effective in the treatment of psoriasis either with nail involvement and/or PsA. Considering the characteristics of this drug, we propose a specific profile of the patient candidate to infliximab treatment. In particular, the main patient characteristics which drive the physician in selecting infliximab include the presence of a severe chronic plaque psoriasis, particularly if it is associated to a severe nail involvement and/or PsA, the urgency of psoriasis clearing, poor compliance of the patient for self-medication and the prospective of a long term continuous treatment.
Collapse
Affiliation(s)
- P Gisondi
- Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
| | | | | |
Collapse
|
21
|
Gisondi P, Malerba M, Malara G, Puglisi Guerra A, Sala R, Radaeli A, Calzavara-Pinton P, Girolomoni G. C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. Int J Immunopathol Pharmacol 2011; 23:1195-202. [PMID: 21244768 DOI: 10.1177/039463201002300423] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Chronic plaque psoriasis is associated to an increased risk of cardiovascular events. The aim of our study is to test patients with psoriasis for common markers of acquired and inherited thrombophilia. A cross-sectional study on 172 patients with psoriasis and 198 controls was carried out. The plasma levels of coagulation protein C, coagulation protein S, homocysteine, folic acid, C-reactive protein (CRP) and fibrinogen as well as activated protein C resistance and antithrombin III activity, were measured. CRP and homocysteine levels were higher in patients with psoriasis than in controls (5.9 ± 7.1 vs 3.1 ± 2.4 mg/L, p=0.0003 and 16.3 ± 12.8 vs 10.4 ± 4.6 umol/L, p=0.0001; mean ± SD) whereas folic acid was lower in psoriatic patients compared to controls (4.3 ± 7.2 vs 12.6 ± 7.9 p=0.006). Levels of coagulation protein C, coagulation protein S, fibrinogen as well as activated protein C resistance, antithrombin III activity were within normal ranges both in cases and controls. In a multivariate regression analysis, psoriasis severity was an independent predictor of higher CRP. In conclusion, high levels of serum CRP and homocysteine were found in patients with psoriasis, related to the severity of the disease. These data suggest that the increased risk of thrombotic cardiovascular events observed in psoriasis patients should be ascribed to an acquired rather than inherited thrombophilic status.
Collapse
Affiliation(s)
- P Gisondi
- Section of Dermatology, Department of Biomedical and Surgical Science, University of Verona, Italy
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Mavilia L, Malara G, Moretti G, Lo Re M, Puglisi Guerra A. Photodynamic therapy of acne using methyl aminolaevulinate diluted to 4% together with low doses of red light. Br J Dermatol 2007; 157:810-1. [PMID: 17635510 DOI: 10.1111/j.1365-2133.2007.08074.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Abbate A, Saffioti G, Malara G, Licordari P, Carrello S, De Pasquale D, Giorgianni C. [Whole-body vibration risk among operators in railway engines shunting ]. G Ital Med Lav Ergon 2007; 29:568-569. [PMID: 18409836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Purpose of the present note is to assess the risk from Whole-body vibration (WBV) in operators employed in the shunting of engines within the railway stations. The study has been conducted in the cockpits of the shunting engines used within the railway station of Villa S. Giovanni (RC). The measures have been taken through accelerometer IHVM 100 Larson-Davis, placed on the seat of each locomotives for a recording time of around 15 minutes. A standard measure has been effected besides, positioning the sensor on the floor of the same locomotives. The measurements indicate that the risk to these workers is negligible because in any case the value is exceeded action daily 0.5 m/s2, having recorded values range from 0.1 to 0.2 m / s2. In conclusion it holds him necessary, to the preventive goals, in respect to how much anticipated from the D.L.gs 187/05 the necessary technical, organizational and formative measures to the containment of the risk.
Collapse
Affiliation(s)
- A Abbate
- Dipartimento di Medicina Sociale del Teritorio Sezione di Medicina del Lavoro Università degli Studi di Messina
| | | | | | | | | | | | | |
Collapse
|
24
|
Sicuro O, Veneziano P, Sidari V, Arcudi L, Carbone L, Ierace M, Malara G, Sgrò E, Veneziano D, Cozzupoli P. Laparoscopic Radical Nephrectomy: A Single Center Experience. Urologia 2005. [DOI: 10.1177/039156030507200205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Renal cell carcinoma has become one of the most important indications for urological laparoscopic surgery. The laparoscopic technique combines the benefits of a minimal invasive approach with basic surgical principles. We report our experience with 52 procedures. Materials and methods Between June 2000 and December 2003 we performed 52 transperitoneal laparoscopic radical nephrectomies for clinical stage T1-T2 renal cell carcinoma. Median age of patients was 59 yrs (range 31–77 yrs). The mean tumor size was 5.4 cm (range 3–12 cm). Results In three patients (5.7%) conversion to open surgery was necessary. The mean operating time was 215 min (150–305 min). Post-operative hospitalization was 5.1 days (3–11 days). Median follow-up was 19.5 months (3–36 months). No cases of local recurrence or port metastasis occurred during observation. Conclusions In our center, a transperitoneal laparoscopic approach with the removal of intact specimens in endobags has become the standard treatment for stage T1-T2 N0 M0 renal cell carcinoma.
Collapse
Affiliation(s)
- O. Sicuro
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| | - P. Veneziano
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| | - V. Sidari
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| | - L. Arcudi
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| | - L. Carbone
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| | - M. Ierace
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| | - G. Malara
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| | - E. Sgrò
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| | - D. Veneziano
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| | - P. Cozzupoli
- U.O. Urologia e Trapianti di Rene, Azienda Ospedaliera Reggio Calabria
| |
Collapse
|
25
|
Affiliation(s)
- L Califano
- Policlinico Universitario-Gazzi, Messina, Italy
| | | | | |
Collapse
|
26
|
Agostini N, Malara G, Mollicone D, Neri F, Cavedon N, Rossi O, Sartore F. Migration of the honey buzzard ( Pernis apivorus) across the central Mediterranean: an ethological approach. ETHOL ECOL EVOL 1993. [DOI: 10.1080/08927014.1993.9523025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
Nival P, Malara G, Charra R, Nival S, Palazzoli I. [Yearly evolution of biomasses of phytoplankton and zooplankton in the Ligurian sea]. C R Acad Hebd Seances Acad Sci D 1972; 275:1295-8. [PMID: 4629629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|